The goal of value-based medicine analyses: Comparability. The case for neovascular macular degeneration

Transactions of the American Ophthalmological Society

Volumn 105, Issue , 2007, Pages 160-169

  Brown, Gary C ^a,b,e   Brown, Melissa M ^a,c,d,e   Brown, Heidi C ^a   Kindermann, Sylvia ^a   Sharma, Sanjay ^f  

^a CENTER FOR VALUE BASED MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Eye Research Institute   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; GOVERNMENT; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INFORMATION RETRIEVAL; LASER COAGULATION; MEDICAID; MEDICARE; METHODOLOGY; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

CHOROIDAL NEOVASCULARIZATION; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG THERAPY; HEALTH STATUS; HUMANS; MACULAR DEGENERATION; PHILADELPHIA; QUALITY OF LIFE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 47749101656     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220-1231.
2. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993;111:1200-1209.
3. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001;119:198-207.
4. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 5. Arch Ophthalmol 2002;120:1307-1314.
5. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - a value-based reappraisal with 5-year data. Am J Ophthalmol 2005;140:679-687.
6. Gragoudas ES, Adamis AP, Cunningham ET, et al, for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
7. Rosenfeld PJ, Brown DM, Heier JS, et al, for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
8. Brown MM, Brown GC, Sharma S, Landy J. Health care economic analyses and value-based medicine. Surv Ophthalmol 2003;48:204-223.
9. Brown MM, Brown GC, Sharma S. Evidence-Based to Value-Based Medicine. Chicago: AMA Press; 2005.
10. Brown GC, Brown MM, Sharma S. Health care in the 21st century: evidence-based medicine, patient preference-based quality and cost effectiveness. Qual Manage Health Care 2000;9:23-31.
11. Brown GC, Brown MM, Sharma S. Difference between ophthalmologist and patient perceptions of quality-of-life associated with age-related macular degeneration. Can J Ophthalmol 2000;35:27-32.
12. Stein JD, Brown MM, Brown GC, Sharma S, Hollands H. Quality of life with macular degeneration. Perceptions of patients, clinicians and community members. Br J Ophthalmol 2003;87:8-12.
13. Stein JD, Brown GC, Brown MM, Sharma S, Hollands H, Stein HD. The quality of life of patients with hypertension. J Clin Hypertens (Greenwich) 2002;4:181-188.
14. Brown MM, Brown GC, Sharma S, Hollands H. Quality-of-life and systemic comorbidities in patients with ophthalmic disease. Br J Ophthalmol 2002;86:8-11.
15. Landy J, Stein J, Brown MM, Brown GC, Sharma S. Patient, community and clinician perceptions of the quality of life associated with diabetes mellitus. Med Sci Monit 2002;8:CR543-548.
16. Redelmeier DA, Detsky AS. A clinician's guide to utility measurement. In: Bergus GR, Cantor SB, eds. Primary Care: Clinics in Office Practice. Vol 22. Philadelphia: WB Saunders; 1995:271-280.
17. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989;5:559-575.
18. Froberg DG, Kane RL. Methodology for measuring health-state preferences - II. Scaling methods. J Clin Epidemiol 1989;42:459-471.
19. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30.
20. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987;40:593-603.
21. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, England: Oxford University Press; 2000:139-199.
22. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839-1845.
23. Brown GC. Vision and quality of life. Trans Am Ophthalmol Soc 1999;97:473-512.
24. Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:82-134.
25. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-481.
26. Heudebert GR, Centor RM, Klapow JC, Marks R, Johnson L, Wilcox CM. What is heartburn worth? A cost-utility analysis of management strategies. J Gen Intern Med 2000;15:175-182.
27. Kallmes DF, Kallmes MH. Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneuryms. AJNR Am J Neuroradiol 1997;18:1453-1462.
28. National Institute for Health and Clinical Excellence (NICE) Web site. Available at. www.nice.org.uk. Accessed Apr 5, 2007.
29. Brown GC, Brown MM, Sharma S. Incremental cost-effectiveness of laser therapy for subfoveal choroidal neovascularization. Ophthalmology 2000;107:1374-1380.
30. Brown GC, Brown MM, Sharma S, Busbee B, Brown H. Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis. Retina 2000;20:331-337.
31. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001;108:2051-2059.
32. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK, Sharma SM. Improvement in quality of life from photodynamic therapy: a Canadian perspective. Can J Ophthalmol 2001;36:332-338.
33. Busbee B, Brown MM, Brown GC, Sharma S. A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina 2003;23:279-287.
34. Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003;7:v-vi, 1-98.
35. Hopley C, Salkeld G, Wang JJ, Mitchell P. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol 2004;88:450-454.
36. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol 2004;88:982-987.
37. Sharma S, Bakal J, Sharma SM, Covert D, Shah GK. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Can J Ophthalmol 2005;40:369-377.
38. Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology 2007;114:1170-1178.
39. Brown MM. The cost-utility of interventions for neovascular macular degeneration. Paper presented at the American Academy of Ophthalmology Retina Subspecialty Course; November 2006; Las Vegas, NV.
40. Trevithick J, Massel D, Robertson JM, Tomany S, Wall R. Model study of AREDS antioxidant supplementation of AMD compared to Visudyne: a dominant strategy? Ophthalmic Epidemiol 2004;11:337-346.
41. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004;88:1107-1112.
42. Bansback N, Davis S, Brazier J. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration. Qual Life Res 2007;16:533-543.
43. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-1246.
44. Busbee B, Brown MM, Brown GC, Sharma S. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology 2002;109:606-612.
45. Busbee B, Brown MM, Brown GC, Sharma S. A cost-utility analysis of cataract surgery in the second eye. Ophthalmology 2003;110:2310-2317.
46. Brown GC, Brown MM, Sharma S, Tasman W, Brown HC. Cost-effectiveness of treatment for threshold retinopathy of prematurity. Pediatrics 1999;104:e47.
47. Brown GC, Brown MM. Is prophylactic PRP in ischemic CRVO a good idea? Rev Ophthalmol 2000;7:106,108,111.
48. Brown GC, Brown MM, Sharma S, Busbee B, Brown H. Incremental cost-effectiveness of therapeutic interventions for branch retinal vein occlusion. Ophthalmic Epidemiol 2002;9:1-10.
49. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. Curr Opin Ophthalmol 2000;11:175-179.
50. Sharma S, Hollands H, Brown GC, Brown MM, Shah G, Sharma SM. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy Curr Opin Ophthalmol 2001;12:230-234.
51. Membreno J, Brown MM, Brown GC, Sharma S, Beauchamp G. A cost-utility analysis of therapy for amblyopia. Ophthalmology 2002;109:2265-2271.
52. Brown GC, Brown MM, Sharma S, Busbee B. A cost-utility analysis of interventions for proliferative vitreoretinopathy. Am J Ophthalmol 2002;133:365.
53. Brown MM, Brown GC. Cost-utility analysis: the foundation of value-based medicine. A cost-utility analysis of senile entropion repair. Evidence-Based Eye Care 2003;4:114-118.
54. Klarman H, Francis J, Rosenthal G. Cost-effectiveness applied to the treatment of chronic renal disease. Med Care 1968;6:48-55.
55. Hollands H, Lam M, Pater J, et al. Reliability of the time trade-off technique of utility assessment in patients with retinal disease. Can J Ophthalmol 2001;36:202-209.
56. Brown GC, Brown MM, Sharma S, Beauchamp G, Hollands H. The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc 2001;99:199-204.
57. Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol 1999;128:324-330.
58. Brown GC, Brown MM, Sharma S, Kistler J. Utility values associated with age-related macular degeneration. Arch Ophthalmol 2000;118:47-51.
59. Brown MM, Brown GC, Sharma S, Kistler J, Brown H. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001;85:327-331.
60. Brown GC, Brown MM, Sharma S, Brown H, Gozum M, Denton P. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications 2000;14:18-24.
61. Brown MM, Brown GC, Sharma S, Brown H, Busbee B. Quality-of-life associated with unilateral and bilateral good vision. Ophthalmology 2001;108:643-647.
62. Brown MM, Brown GC, Sharma S, Landy J. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002;120:481-484.
63. Brown MM, Brown GC, Sharma S, Smith AF, Landy J. A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes. Int Ophthalmol 2001;24:123-127.
64. Brown GC, Brown MM. Quality-of-Life Utility Database. Flourtown, PA: Center for Value-Based Medicine Press; 2007.
65. Sharma S, Oliver A, Bakal J, Hollands H, Brown GC, Brown MM. Utilities associated with diabetic retinopathy: results from a Canadian sample. Br J Ophthalmol 2003;87:259-261.
66. Kobelt G, Jonsson B, Bergstrom A, Chen E, Linden C, Alm A. Cost-effectiveness in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand 2006;84:363-371.